Lawrence F. Eichenfield

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.

Nailed it? A diagnostic puzzle in an infant

Focused update: Guidelines of care for the management of atopic dermatitis in adults

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis

Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study

Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( <scp>INTEGUMENT</scp> ‐ <scp>PED</scp> ): A Phase 3 Randomized Controlled Trial

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.

Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children

Impact of climate change on atopic dermatitis: A review by the International Eczema Council

A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council

Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients

Impact of climate change on atopic dermatitis: A review by the International Eczema Council.

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

A large language model artificial intelligence for patient queries in atopic dermatitis

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to &lt;18 years old: a randomized clinical trial of extended treatment to 3.6 years

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.

Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies.

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.

Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.

Successful topical minoxidil treatment for hair density and length in trichorhinophalangeal syndrome type 1.

Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.